Clinical Trial Results:
A Randomized, Global, Phase 3 Trial of Nivolumab Plus Epacadostat in Combination with Chemotherapy (platinum + 5-fluorouracil) versus the EXTREME Regimen (cetuximab + platinum + 5-fluorouracil) in First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Summary
|
|
EudraCT number |
2017-003305-18 |
Trial protocol |
ES |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Aug 2021
|
First version publication date |
20 Aug 2021
|
Other versions |
|
Summary report(s) |
Study Withdrawal |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.